AIM ImmunoTech Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
AIM completed patient enrollment and dosing in the DURIPANC Phase 2 trial testing Ampligen combined with AstraZeneca's Imfinzi in metastatic pancreatic cancer. Cash position improved from $3.0M (Dec 2025) to $9.9M (June 2026) through multiple financing transactions. The company expects clinical benefit data in Q1 2027 and Overall Survival data in Q3 2027, targeting Phase 3 development; it also plans government-funded Ebola initiatives. Q2 2026 net loss was $3.8M ($0.43/share).
Why this rating
Trial completion and 3.3x cash boost represent material progress for $6.4M market-cap biotech. Meaningful but unproven—Phase 2 data timing and Phase 3 success remain uncertain.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.